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Crucial for chronic lymphocytic leukaemia (CLL) development and 
progression are the iterative cycles of cell re-activation and proliferation that take 
place in lymphoid tissues. These iterative cycles are fundamental for the 
development and the progression of the disease. 
Since cellular fatty acid (FA) import and oxidation (FAO) were recently 
reported to be upregulated in CLL, compared to normal B lymphocytes, we 
explored the in vitro effects of ST1326, a reversible inhibitor of carnitine-
palmitoyl transferase 1A (CPT1A), on leukaemic cells subject to activating 
microenvironment-mimicking stimuli. 
ST1326 induced dose-dependent mitochondrial dysfunction and cell death, 
which were remarkably higher in activated/proliferating than quiescent CLL 
cells. Drug sensitivity was observed irrespective of the presence of TP53 
alterations or chromosomal abnormalities, which are known to cause 
chemoresistance in CLL patients.  
The treatment of normal B lymphocytes with ST1326, at doses lethal to CLL 
cells, causes only a slight inhibition of cell activation/proliferation, indicating a 
modest cytostatic, not cytotoxic, effect. 
ST1326 cytotoxicity in CLL was associated with decreased levels of 
intracellular Acetyl-CoA and down-regulation of signalling pathways that are 
crucial for leukaemic cell survival, activation and proliferation. In particular, 
environment-induced activation of STAT3 and STAT6 transcription factors, 
known to upregulate anti-apoptotic Bcl-2 family members Mcl-1 and Bcl-xL, 
was impaired by ST1326. As a consequence, drug combination experiments with 
the BH3-mimetic ABT-199/Venetoclax, whose effects are counteracted by Mcl-
1/Bcl-xL and cell proliferation, showed strong ST1326-mediated potentiation of 
ABT-199 cytotoxicity in activated/proliferating CLL cells. We also observed 
that ST1326 showed a synergic effect with Fludarabine in activated/proliferating 
CLL cells. 
The data indicate that CLL cells turning to an activated/proliferating state 
become more dependent on FAO and more sensitive to FAO-antagonists, and 
pave the way for ST1326 as an adjuvant tool in anti-CLL drug-combination 





Chronic lymphocytic leukaemia 
Epidemiology and Incidence 
Chronic lymphocytic leukaemia (CLL) is the most common B-cell 
malignancy in the Western world. It represents 22-30% of all leukaemia cases 
with a worldwide incidence between <1 and 5.5 per 100,000 people. In particular, 
Australia, the USA, Ireland and Italy have the highest CLL incidence rates (1).  
The median age of diagnosis in the USA, Europe and Australia is 
approximately 70 years of age (1; 2). 
Development of CLL is higher in white people than in black people and in 
males than in females, with an M/F sex ratio of at least 1.5 or higher (3). 
Additionally, males are more likely to have disease progression and require 
therapy (3; 4).  
In Italy, the 2006 Report of the Italian Network of Cancer Registries provided 
evidence that, in the 1998-2002 period, CLL was the most frequently diagnosed 
leukaemia, representing about 33.5% of all leukaemia. It has been reported that 
the incidence of new cases of CLL is around 1600 for men and 1150 cases/year 
for women. 
Diagnosis 
In the presence of ≥ 5 000 monoclonal B-cells per μl in peripheral blood, 
over a period of more than 3 months, the diagnosis of CLL is commonly 
established by immunophenotyping.  CLL cells co-express B and T cell surface 
antigens: CD19, CD20, CD23 and CD5 respectively. Furthermore, leukaemic 
cells derived from the same clone express the same immunoglobulin heavy chain, 
either kappa or lambda.  
Recently, it has been confirmed that a panel of CD19, CD5, CD23, κ, λ and 
CD20 is sufficient for the diagnosis of CLL. In borderline cases, markers such as 
ROR1, CD79b, CD43, CD200, CD10 or CD81 could help the diagnosis (5). 
 
In the presence of < 5 000 monoclonal B-cells per μl in the peripheral blood 
and no other features of lymphoproliferative disorder, the diagnosis is 
“monoclonal B-lymphocytosis” (MBL), a precursor state of chronic lymphocytic 
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leukaemia. Subjects with MBL, like CLL patients, show an increased risk of 
secondary cancers, in particular skin cancer (5). 
CLL staging 
The definition of the CLL stage is based on the natural history of the disease. 
According to the European Binet staging system (developed in 1981), CLL is 
divided into three stages (A, B and C) (6). This system is based on the number of 
areas involved. Patients in Binet stage A have 0 to 2 affected lymph node areas 
or organ enlargement with normal levels of haemoglobin and platelets. Binet 
stage B patients have peripheral and medullary lymphocytosis and 3 to 5 affected 
lymph node areas. Binet stage C patients have peripheral and medullary 
lymphocytosis with Hb <10 g/dl and/or thrombocytopenia (<100,000/mm3). 
In the USA, the most common clinical staging system used is the Rai staging 
system developed by Dr Kanti Rai in 1975 (7). This method is based on the 
concept that CLL is an accumulative pathology. The Rai staging system divides 
the CLL disease into five (0-IV) different stages that are described in the Kanti 
R. Rai et al. paper as follows: 
- 0, lymphocytosis in blood as well as in bone marrow (absolute 
lymphocytes, 15,000/cu mm or more in blood, 40% or more lymphocytes in the 
marrow).  
- I, lymphocytosis with enlarged lymph nodes.  
- II, lymphocytosis with enlarged spleen or liver or both. Nodes may or may 
not be enlarged.  
- III, lymphocytosis with anaemia. Nodes, spleen, or liver may or may not be 
enlarged.  
- IV, lymphocytosis with thrombocytopenia. Anaemia and organomegaly 
may or may not be present.  
Patients belonging to the stage Binet B or Rai stage I/II are considered as 
intermediate-risk groups while patients belonging to the stage Binet C or Rai 
stage III/IV are defined as being in the high-risk categories. 
For the overall status of the patient and the disease progression these two 
staging systems are very helpful, but they are unfit for the prediction of disease 
evolution. On the contrary, molecular prognostic markers are more useful for 
predicting patient survival, disease progression and resistance to therapy. 
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Prognostic markers  
In CLL, the most important prognostic factors are: 
- genetic parameters, including the cytogenetic aberrations, mutational status 
of IGHV genes (8) and gene mutations, in particular TP53 (9); 
- cell markers, including CD38 (10) and ZAP70 (11); 
These parameters allow the stratification of the patients into different risk 
categories.  
 
By using predominantly fluorescence in situ hybridization (FISH), different 
types of genomic aberrations have been identified. 
The most common cytogenetic abnormality (in about 50% of CLL patients) 
is the deletion of the 13q14 region and subsequent loss of miRNAs (miR-15a and 
miR-16-1), which initiates leukaemogenesis. Usually, patients with this deletion 
have a good prognosis, even if, recently, it has been shown that a large deletion 
of 13q is associated with poor prognosis (12; 13). The other most common 
genetic abnormalities are represented by: 
- the deletion of chromosome 11q22-q23, which is found in 10–20% of cases, 
causes the loss of the ataxia telangiectasia mutated (ATM) gene that encodes a 
DNA damage response kinase, ATM, that is very important in DNA damage 
detection and induction of cell cycle arrest. This alteration defines a subgroup of 
patients with unfavourable prognosis (13);  
- trisomy 12, its prognostic relevance is still debate (14);  
- deletion of chromosome 17p13 (del (17p13)), which occurs in 5–8% of 
cases, causes the loss of the tumour suppressor gene p53 (TP53) that is involved 
in the DNA damage detection pathway, cell cycle arrest, apoptosis and regulation 
of cellular metabolism (15). Commonly, this type of alteration is acquired at the 
late stages of the disease particularly after treatment. Deletion of 17p13 is 
associated with poor survival and high risk of resistance to chemotherapeutic 
agents (16). Therefore, patients that harbour this aberration are included in the 
highest risk prognostic category (17). 
The somatic hypermutation status of the IGHV gene has a very important 
prognostic role.  
B lymphocytes are known to recombine immunoglobulin variable (V), 
diversity (D), and junction (J) genes during their development, to create a unique 
antigen binding domain of the B cell receptor (BCR). In order to generate high-
affinity antibodies, a second process namely somatic hypermutation occurs. This 
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process is triggered when the Ig binds the antigen and consists of the 
accumulation of point mutations in the V regions.  
The presence or not of somatic mutations in the IGHV gene of leukemic cells 
divides CLL patients into two groups: unmutated CLL (U-CLL), with a germline 
identity ≥98%, who have an aggressive disease course, and mutated CLL (M-
CLL) with a germline identity <98% who usually have a more indolent disease 
(8; 18). 
Somatic mutations can occur in the tumour suppressor gene p53 leading to a 
deterioration in its function (9). It is well known that p53 exerts its tumour 
suppressive activities by inducing cell cycle arrest and apoptosis (9; 19). It has 
been reported that these functions are also related to the capability of p53 to 
regulate cellular metabolism and maintain cellular oxidative homeostasis (15; 
20). In particular, p53 reduces lipid synthesis and promotes lipid degradation 
by inducing the expression of carnitine palmitoyltransferase 1 (CPT1) (20), the 
rate-limiting enzyme for the entry of fatty acids into mitochondria where lipid 
degradation occurs.       
Patients harbouring these mutations are characterized by an aggressive 
disease course and resistance to chemotherapy and chemoimmunotherapy, as is 
well documented by a variety of studies (9; 16; 21), including prospective 
clinical trials (22; 23). It has been shown that in about 5% of untreated patients, 
TP53 mutations take place in the absence of del (17p13) while in about 70% of 
cases, TP53 mutations can occur together with del (17p13) leading to a double 
mechanism of inactivation (9). It has to be highlighted that TP53 represents an 
independent adverse prognostic marker for progression free-survival (PFS) and 
overall survival (OS) in CLL patients (9).  
 
Recently, thanks to the use of next generation sequencing, new genomic 
abnormalities have been identified, for example i) activating mutations of 
NOTCH1, which occur in about 10% of CLL patients at diagnosis and are 
associated with poor prognosis, poorer responses to conventional 
chemoimmunotherapy and increase in the risk of transformation to diffuse large 
B-cell lymphoma (DLBCL) (24); and ii) dysfunctional mutations of Splicing 
factor 3b, subunit 1 (SF3B1), which occur in about 5%-15% of patients with CLL 
at diagnosis and are related to poor overall survival, faster disease progression 
and chemoresistance (25; 26).  
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CD38 is a transmembrane glycoprotein that is commonly expressed at high 
levels in plasma cells, germinal centres B cells, B cell precursors and, with low 
expression, on circulating B cells (27). The natural ligand of CD38 is CD31, an 
adhesion molecule expressed by different cell types in the CLL 
microenvironment, such as “nurse like cells” (NLCs) and T lymphocytes. The 
binding between CD38 and CD31 leads to survival and proliferation signals in 
leukaemic cells (27). CD38 is defined as a negative prognostic marker for 
patients with CLL (27). In the majority of studies, the threshold, that provides the 
best prognostic value, is CD38+ ≥ 30% (10). 
Like CD38, ZAP-70, a member of the syk tyrosine kinase family, is a 
negative prognostic marker for patients with CLL (11). 
Biology of CLL and the microenvironment     
CLL is characterized by the accumulation of CD5 and CD19 positive 
monoclonal B cells in the peripheral lymphoid organs, bone marrow and blood 
(28; 29). CLL cells are phenotypically similar to mature B cells that have 
encountered the antigen. Indeed, they express high levels of surface molecules 
(CD23, CD20 dim, CD69) and low levels of markers downregulated after cellular 
activation, such as CD22, receptor gamma Fc IIb and CD79b (29). Furthermore, 
the expression levels of surface immunoglobulin, CD20, CD79b and CD19 are 
usually low compared with normal B cells. Yet, they express a typical marker of 
the memory B-cell, CD27 (30) and also the gene expression profiles are similar.  
 
In the past, CLL cells were considered to be quiescent apoptosis-resistant 
malignant B lymphocytes. This resistance was associated with the over-
expression of the anti-apoptotic protein Bcl-2 (31). CLL was in fact described as 
a “pathology of accumulation”, considering the defect in the apoptotic 
mechanism as one of the main causes of the disease. Over time, different studies 
on CLL biology revealed a new dynamic view of this disease (32). It became 
clear that CLL cells undergo, during their life, iterative cycles of re-activation 
and subsequent clonal expansion, before coming back to a quiescence state. By 
using a deuterium oxide 2H in vivo labelling method, in which patients consumed 
deuterated (heavy) water (2H2O), it has been shown that the daily growth rate of 
CLL cells ranges from 0.08% to 1.7% (33). Furthermore, by using this same 
method, it has also been demonstrated that the lymph nodes are the anatomical 
site harbouring the largest fraction of newly born cells compared to peripheral 
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blood and bone marrow (34). This supports the concept that activation and clonal 
expansion occur in lymphoid proliferation centres within secondary lymphoid 
tissues, where multiple molecular interactions with antigen and 
microenvironment contribute to leukaemic B cell survival, chemoresistance and 
proliferation.  
The tumour microenvironment (TME) is a very complex milieu in which 
signals, fundamental for the survival and accumulation of leukaemic cells, are 
delivered by soluble factors or direct cell contact. An important interaction that 
rescues CLL cells from apoptosis, both in vivo and in vitro, is represented by the 
binding between CD38, expressed on CLL cells, and its natural ligand CD31, 
expressed on NLCs (35) and T lymphocytes (29). Bone marrow stromal cells 
(BMSC) (36), the predominant stromal cell population in the CLL 
microenvironment, can also protect CLL cells from apoptosis and support their 
proliferation. Crucial for supporting growth and survival of leukaemic cells is the 
binding between CD40, expressed on CLL cells, and CD40 ligand (CD40L), 
expressed on activated CD4+ T helper lymphocytes (29; 37). In addition, T cells 
secrete different types of cytokines, including IL-4 and IL-21, that play an 
important role in supporting CLL cells proliferation (29; 37; 38).  
Another soluble factor that might support the clone expansion is represented 
by CXCL12 (stromal cell-derived factor 1, SDF-1), a natural ligand of the 
chemokine receptor CXCR4 that is overexpressed on CLL cells. CXCL12 is 
secreted by NLCs and, after binding CXCR4, promotes the up-regulation of anti-
apoptotic genes, like Bcl-2 and Mcl-1, favouring the survival of leukaemic cells 
(29). Also IL-6, produced by endothelial cells, inhibits apoptosis of B-CLL cells 
(39). 
 
Taken together, these results indicate a dynamic picture where CLL cells 
undergo iterative cycles of re-activation and subsequent clonal expansion in the 
lymphoid microenvironment, which crucially contribute to CLL disease 
progression. 
CLL treatment 
Since CLL disease is still an incurable disease, its pharmacological treatment 
remains a subject of considerable interest and relevance. Patients with CLL have 
a variable disease course with a third of patients never needing treatment and, on 
the other hand, other patients that need treatment soon after diagnosis. The 
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criteria for initiating treatment in CLL patients depend on the symptoms caused 
by the disease and also on the Binet/Rai staging systems. In particular, patients 
with asymptomatic, early-stage disease (Rai 0; Binet A) are usually not treated 
but are followed on a "watch and wait" principle (6; 7; 13). On the contrary, 
patients with signs of active disease (i.e. rapidly progressive lymphadenopathy) 
or classified as Binet stage C or Rai stage III and IV, are subjected to treatment 
(6; 7; 13).  
For several decades, the “gold standard” treatment for CLL was represented 
by the alkylating agent chlorambucil (40). It was discovered in the ‘90s that the 
combination of cyclophosphamide, another alkylating agent, and the purine 
analogues Fludarabine improved the quality and duration of response in younger 
patients (41). 
Fludarabine (FAMP) is the most studied and effective purine analogue in B-
CLL. The purine analogues act by mimicking the purine’s structure and after 
their incorporation into DNA or RNA,  they inhibit the cellular replication and 
transcription. Fludarabine is also able to induce cell death in quiescent cells by 
the activation of the mitochondrial pathway of the apoptotic cascade (42). 
However, a considerable clinical problem is the development of 
chemoresistance. This might be due to genetic alterations, like MYC 
overexpression (43), del(17p) (16) and/or TP53mutations (16), but is also 
markedly influenced by the TME, which induces the expression of anti-apoptotic 
Bcl-2 family proteins (44), thus contributing to chemoresistance (45; 46). As an 
example, the Mcl-1/Bax ratio and also Bcl-2/Bax ratio was reported to correlate 
with chemoresistance to Fludarabine (45; 47). Also, the induction of both Bcl-xL 
and A1 in CLL was associated with chemoresistance to Fludarabine in preclinical 
models (48).  
 
Drugs that target two fundamental kinases involved in the transduction of 
signals from the BCR, namely the Bruton’s tyrosine kinase (BTK) and the 
phosphatidylinositol 3-kinase (PI3K) δ isoform, have been developed in recent 
years.  
The BTK pathway is amplified in CLL, where this kinase is constitutively 
phosphorylated, and leads to pro-survival signals and induction of proliferation 
by its effect on AKT (49), nuclear factor-KB (NF-KB) (50) and extracellular 
signal-regulated kinase (ERK) (51).  
PI3K is a family of enzymes involved in crucial cellular activities such as 
proliferation, survival, metabolism, migration and genomic instability (52; 53). 
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PI3Kδ isoform expression is restricted to leukocytes and plays a central role in 
the survival of normal B cells. In CLL cells the PI3K pathway is constitutively 
activated and dependent on PI3Kδ (54). Therefore, these two kinases represent a 
very good target for the CLL disease. Ibrutinib (PCI-32765), a covalent inhibitor 
of BTK, and Idelalisib (GS-1101 or CAL-101), a selective and reversible 
inhibitor of PI3Kδ, were particularly successful among drugs developed for 
inactivating these kinases. They are able to reduce, both in vitro and in vivo, cell 
survival, migration and proliferation (54; 55; 56) of CLL cells and are currently 
FDA approved for patients with relapsed or refractory CLL and also in patients 
with TP53 aberrations (57; 58). 
However, recent data report the development of CLL cells resistances to 
Ibrutinib (59; 60). Also, immune-mediated toxicity like neutropenia and sepsis, 
hepatotoxicity and pneumonitis have been reported in patients on Idelalisib (61).  
 
Another drug that showed a remarkable clinical response in CLL, 
independently from negative prognostic markers like TP53 aberration (62), is the 
B-cell lymphoma 2 (Bcl-2) Homology 3 (BH3)-mimetic Venetoclax (ABT-199).  
CLL cells rely on the activity of anti-apoptotic Bcl-2 family members for 
their survival (63). Therefore, strategies to restore apoptosis in CLL cells by 
antagonizing the anti-apoptotic proteins have led to the development of BH3 
mimetics as therapeutic agents (64; 65; 66; 67; 68). BH3-mimetics are small 
molecules modelled on the BH3 domains of BH3-only members (66). They 
mimic their function by binding to anti-apoptotic Bcl-2 family proteins, thus 
leading to the inhibition of their activity. In this way, Bax and Bak are released, 
causing the trigger of apoptosis (63; 67).  
The prototype of these small molecules was ABT-737, which mimics the 
pro-apoptotic protein Bad (68). Its oral derivative is Navitoclax (ABT-263) that 
binds, with high affinity, the anti-apoptotic proteins Bcl-xL, Bcl-W and Bcl-2 but 
not Mcl-1 (67). It has shown promising results in haematological malignancies, 
especially in CLL (69). However, ABT-263 provoked severe thrombocytopenia 
due to on-target toxicity on the Bcl-xL protein, which is a fundamental survival 
molecule for the platelets (67; 69; 70). In order to avoid this important side effect, 
the second-generation compound ABT199 (called also Venetoclax) was 
designed for specifically binding Bcl-2 (64; 65) sparing thus Bcl-xL and platelets. 
In particular, ABT199 shows a subnanomolar affinity for Bcl-2, no interaction 
with Mcl-1 and very weak affinity for BcL-xL and Bcl-W (64). This drug has 
been demonstrated to be efficacious in leukaemia/lymphoma Bcl-2 dependent 
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cell lines and also in tumour xenograft models (64). Its effect seems superior in 
CLL than in other lymphoid malignancies, although evidence in mantle cell 
lymphoma and lymphoplasmacytic lymphoma is encouraging (71). In recent 
times, a phase I (65) and a phase II (62) studies have proved that Venetoclax 
monotherapy is active also in patients with relapsed or refractory del(17p). 
However, the cytotoxic activity of this BH3-only mimetic is impaired when 
anti-apoptotic proteins, like Mcl-1 and Bcl-xL, are overexpressed (72; 73). 
Recently, Tahir S.K. et al. have shown that in leukaemic and lymphoma cell lines 
resistant to ABT199 there is an increased expression of the anti-apoptotic 
proteins Mcl-1 and Bcl-xL, which are not targeted by ABT199 (73). The work of 
Thijssen R. et al. analysed in CLL cells to what extent microenvironmental 
signals can alter sensitivity to ABT-199 (72). They reported that unstimulated 
CLL cells are highly sensitive to ABT-199 (LC50<1nM) rather than CD40 and 
CD40+IL-4 stimulated CLL cells that show to be fully resistant to 10  M ABT-
199. This might be due to the over-expression, in the proliferating CLL cells, of 
anti-apoptotic proteins that are not targeted by ABT199, like Mcl-1 and Bcl-xL 
(72). 
Altogether, it appears that the microenvironment and subsequent CLL cells 
activation/proliferation reduce CLL cell sensitivity to Venetoclax. 
 
Following the above considerations, new therapeutic and adjuvant strategies 
are needed.  
In recent years, an emerging role of fatty acids (FAs) metabolism in cancer 
cells has been recognised. During tumour progression, lipid metabolism assumes 
important roles by providing energy for the proliferation and macromolecules for 
membrane synthesis. Therefore, targeting FAs metabolism in cancer cells, 
including CLL, may represent a novel therapeutic strategy.  
Lipid metabolism and carnitine palmitoyltransferase 1A (CPT1A) 
inhibitor  
CLL cell energetic metabolism is nurtured not only by glycolytic 
mechanisms but also, unlike normal B lymphocytes, by fatty acid oxidation 
(FAO; known also as β-oxidation) (74).  
FAO consist of a cyclical series of reactions, in the mitochondrial matrix, in 
which FAs are repeatedly cleaved to produce Acetyl-CoA, which then enters the 
Krebs cycle, and reducing equivalents, NADH and FADH2, which in turn enter 
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oxidative phosphorylation. Since FAO takes place in the mitochondrial matrix 
and FAs are negatively charged, a specialized carnitine carrier system is needed 
to allow the entry of long-chain FAs into the mitochondria. This carrier system 
is composed by CPT1, carnitine/acylcarnitine translocase (CACT) and CPT2, 
that work together in order to transport long-chain fatty acids into the 
mitochondria. First of all, FAs must be activated through two reactions catalyzed 
by the enzyme fatty Acyl-CoA synthetase. The Acyl-CoA obtained from these 
reactions can be now transported into the mitochondrial matrix where FAO 
occurs. The first actor and rate-limiting step for the entry of FAs into the 
mitochondria is represented by the enzyme CPT1, which is a protein of 
approximately 88 kDa tightly associated with the outer membrane of 
mitochondria. CPT1 acts by transferring acyl-group from coenzyme A onto 
carnitine; its activity is physiologically inhibited by Malonyl-CoA (75), a 
substrate for fatty acid synthesis. 
Inhibition/depletion of CPT1 causes apoptosis, the block of cancer cell 
proliferation and suppression of chemoresistance (76; 77), thus making this 
enzyme an eligible target for drugs in human cancer, including CLL. There are 3 
different isoforms of CPT1: CPT1A found in liver and also in other cells except 
for skeletal muscle cells and brown adipose cells, CPT1B typical for the muscle 
cells and brown adipose cells and CPT1C that is expressed only in the neuron. 
The isoform CPT1A is frequently related to tumour progression in several 
cancers e.g. myeloma, gastric, breast, prostate, ovarian, lung, lymphoma, and 
leukaemia cancer (78; 79; 80; 81). In particular, the CPT1A isoform (82; 83), like 
other molecules implicated in the lipid metabolism such as lipoprotein lipase 
(LPL) (74) and nuclear receptor peroxisome proliferator-activated receptor 
(PPAR)-α (74), are all overexpressed in CLL cells if compared to normal B 
lymphocytes.   
CPT1A can preserve cells from apoptosis by removing the long-chain fatty 
acyl-CoA from the cytoplasm avoiding the accumulation of free fatty acids that 
cause mitochondrial membranes damage and cell death (76; 84; 85). In particular, 
the FAs accumulated in the cytoplasm may activate, in virtue of their detergent 
properties, Bax (85) a pro-apoptotic protein that causes the trigger of apoptosis 
through the release of cytochrome c from the mitochondria (63; 67). Thus, CPT1 
activity is extremely important in order to avoid the accumulation of free FAs 
and protect, in this way, the cell from apoptosis.  
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A selective, reversible CPT1A inhibitor, (R)-N-(tetradecylcarbamoyl)-
aminocarnitine (ST1326), was recently developed (86; 87). ST1326 (Teglicar) is 
an aminocarnitine derivative that was initially selected by Sigma-Tau 
laboratories as a candidate for diabetes and ketoacidosis therapy (86). In phase 2 
studies for the treatment of type 2 diabetes, it demonstrated an excellent safety 
profile (87). Moreover, data in the literature revealed encouraging results in the 





Aim of the study 
 
The scope of our investigation was to assess the sensitivity to ST1326 of 
leukemic cells derived ex-vivo from the peripheral blood of CLL patients, in an 
environment-mimicking context, where leukemic cells are challenged with 
activation stimuli that render them generally refractory to current therapeutic 
regimens and are responsible for disease progression. 
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Materials and Methods 
 
CLL cells and drugs 
 
CLL cells were obtained from the peripheral blood (PB) of CLL patients, 
following informed consent in accordance with the Declaration of Helsinki. 
Mononuclear cells separated by Ficoll density gradient centrifugation were 
assessed by flow cytometry (FACS Calibur, BD Biosciences, San Diego, CA) 
for standard diagnostic immunophenotyping (CD19, CD5, CD23, CD79B, 
CD22, CD38) and identification of heavy chain (IgM, IgG or, very rarely, IgA) 
and light chain (kappa or lambda) isotype. Cells were then resuspended in 
freezing solution (10% DMSO and 90% Fetal Bovine Serum (FBS)) and 
cryopreserved in liquid nitrogen. Samples from CLL patients that containing at 
least 95% of leukaemic cells were considered eligible for the study. Clinical and 
molecular characteristics of the CLL patients utilized in this study are shown in 
Table 1. 
Cell cultures of CLL cells were performed by seeding thawed cells into 
RPMI (Invitrogen S.r.l., Milan, Italy) culture medium supplemented with 10% 
FBS (Invitrogen) at high cell density, 4×106/ml in 48-well plates each containing 
0.5 ml of culture medium. We used two different in vitro stimulation models. In 
the first model, in vitro activation of CLL cells was achieved by co-culturing 
leukaemic cells with a stable CD40L-expressing NIH-3T3 murine fibroblast cell 
line (CD40L-NIH-3T3), produced in our laboratory (88), at a cell number ratio 
1:100 (fibroblasts:CLL cells). Recombinant human interleukin 4 (IL-4) 
(PeproTech Inc.) or, in a few cases, recombinant human interleukin 21 (IL-21) 
(PeproTech Inc.) were added in the culture at final concentrations of 12.5 ng/ml 
and 25 ng/ml respectively.  
In a second in vitro stimulation model, quiescent CLL cells were cultured in 
the presence of CpG DNA Toll-Like Receptor-9 (TLR-9) ligand, called 
ODN2006 (Invivogen), and recombinant human IL-15 (PeproTech Inc.) at final 
culture concentrations of  2 g/ml and 10 ng/ml respectively (89; 90). In addition 
to the soluble stimuli (CpG ODN+IL-15) in a few experiments, the CLL cells 
were cultured in the presence of a murine line of BMSC seeded at a concentration 
of 1.6x104 in 48 well plates. 
In vitro response to activation stimuli were assessed flow cytometrically by 
increased expression of activation molecules (CD80, CD86, HLA-DR, CD25, 
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CD69, CTLA-4), increased cell size (forward light scattering) and % cells in 
S+G2M cell cycle phases (DNA content histograms).  
 
Normal B lymphocytes were obtained from the PB of healthy volunteers. 
Mononuclear cells were isolated by Ficoll density gradient centrifugation as a 
pre-separation step. Normal B cells were isolated by negative selection using a B 
cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) according to 
the manufacturer's instructions. We performed an immunofluorescence staining 
with FITC-conjugated CD3 and PerCP-conjugated CD19 mAbs (BD 
Biosciences, San José, CA) to verify B lymphocytes purity.  
Cell cultures of normal B lymphocytes were performed by seeding purified 
cells into RPMI culture medium supplemented with 10% FBS at 2×106/ml in 48-
well plates each containing 0.5 ml of culture medium. In vitro activation of B 
cells was achieved by co-culturing B-lymphocytes with CD40L-NHI3T3 
fibroblast and IL-4 at final culture concertation of 12.5 ng/ml. 
 
ST1326 (Teglicar) was kindly provided by Sigma-Tau IFR S.p.A., Rome, 
Italy (Alfasigma S.p.A Group) and was dissolved in DMSO at the concentration 
of 50 mM and stored at -20°C.  
 
Etomoxir sodium salt hydrate (Sigma, Saint Louis, Missouri, USA) was 
dissolved in H2O at the concentration of 10 mM and stored at -20°C.  
 
In drug-combination tests, ST1326 was added to the cells simultaneously to 
a second drug: Fludarabine monophosphate from Schering AG (Berlin, 
Germany), ABT-199 from LC Laboratories (Woburn, MA, USA), Ibrutinib or 
Idelalisib (GS-1101, CAL-101) both from PeproTech Inc. 
 
Drug treatment on stimulated CLL cells was performed simultaneously to 







Flow-cytometric assays for cell viability, mitochondrial 
transmembrane potential (ΔΨ), proliferation and apoptosis 
  
Cellular viability was assessed by Propidium Iodide (PI) exclusion assay. 
Cells were incubated with 1 μg/ml PI (Sigma Chemical Co., St Louis, MO, 
USA) for 5 minutes (min) at room temperature (RT). PI fluorescence was 
measured by flow cytometry (FACS Calibur, BD Biosciences, San Diego, CA). 
Cells positive for PI fluorescence were considered dead cells.  
 
Loss of mitochondrial transmembrane potential (ΔΨ) was evaluated by 
decreased fluorescence of the cationic dye 3,3′-dihexyloxacarbocyanine iodide 
(DiOC6). Leukaemic cells were incubated for 15 min at 37°C with 40 nM DiOC6 
and analysed by flow cytometry (FACS Calibur, BD Biosciences, San Diego, 
CA). At least 5,000 events were acquired per sample on a logarithmic scale.  
 
Flow-cytometric analysis of DNA content was performed on cells 
permeabilized with 0.05% Triton X-100 and stained with 30 μg/ml 
PI+0.5 mg/ml RNase for 30 min at 37°C. DNA content histograms provide 
information on proliferation (cell-cycle-phase distributions) and apoptotic 
DNA fragmentation (cells in the ‘sub-G0/G1’ region, that is, cells with a DNA 
content lower than that of cell cycle G0/G1-phase cells). 
 
Cellular externalization of phosphatidylserine molecules was assessed by 
flow cytometric measurements of Annexin V binding on cells stained with 
Annexin V-FITC, according to standard manufacturer instructions (BioVision, 
Mountain View, CA, USA). 
 
Protein expression by flow cytometry 
 
Analysis of protein levels, expressed on the plasma membrane or 
intracellularly, was performed by immunofluorescence and flow cytometry on a 
FACS Calibur.  
Antibodies to surface proteins were CD80, CD69 and CD25, all from BD 
Pharmingen (San Diego, CA). Antibodies to intracellular proteins were rabbit 
polyclonal anti-Mcl-1 (H-260), anti-Bcl-xL (H-5) all from Santa Cruz 
Biotechnology (San Diego, CA) and used at 20 μg/ml; phospho NFKB p65 
(Ser536), anti-STAT3 (pan), phospho STAT3 (Tyr705) and phospho STAT3 
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(Ser727) antibodies all from Cell Signaling Technology, Inc. and anti-Bax clone 
3 from BD Biosciences, San José, CA.  
Cells were fixed with 3% paraformaldehyde (PFA) and permeabilized with 
0.1% Triton X-100 for Mcl-1, Bcl-xL and Bax, or 3% PFA followed by ice-cold 
methanol, 8 min, for pSTATs. Secondary antibodies conjugated to Alexa 
fluorochrome were from Molecular Probes (Invitrogen, Eugene, OR).  
For evaluation of NFKB p65 (Ser536) expression in leukaemic cells, nuclear 
extracts were obtained from CD40L stimulated CLL cells, either untreated or 
treated with 15 M ST1326 for 24h. The nuclear pellet derived from lysates 
centrifugation, see paragraph Immunoblotting for more details, were fixed with 
1% PFA for 10 min at RT and stained as mentioned before. 
 
KI67 expression was assessed with FITC-conjugated KI67 mAb (BD 
Pharmingen, San Diego, CA). The cells were fixed with ice-cold 70% ethanol, 
incubate over-night at -20°C and stained for the detection of Ki-67 following 
manufacturer’s instructions. When KI67 was analyzed in conjunction with DNA 
content to achieve bivariate plots of KI67 expression/cell cycle phase 
distributions, CLL cells were also incubated with 30 μg/ml PI and 0.5 mg/ml 
RNase for 30 min at room temperature in the dark. 
 
It is important to highlight that the analysis of protein expression by flow 
cytometry was restricted to viable leukaemic cells (thus gating out late apoptotic 
cells), namely cells falling within the ‘live’ gate on flow cytometric FSC-SSC 
plots, i.e. the ‘high FSC-low SSC’ gate. This compartment contains CLL cells 
that still have intact ∆Ψ, an intact plasma membrane and do not express activated 
caspase 3 (91). CLL cells outside the gate, with ‘low FSC-high SSC’ features, 
are mostly late apoptotic and dead cells and are not reliable for intracellular 
immunofluorescence assays because of unspecific staining that easily occurs on 
dead cells. By this approach, early changes of protein expression can be 
discriminated from consequences of late apoptotic steps.  
 
Measurements of Acetyl-CoA and intracellular neutral lipids 
 
Acetyl-CoA levels were measured by colourimetric tests using the PicoProbe 




To measure intracellular levels of neutral lipids and lipid droplets, cells were 
stained with the lysochrome diazo dye Oil Red O (Sigma-Aldrich, 
http://www.sigmaaldrich.com) (working solution, 0.5g Oil Red O powder 
dissolved in 60% propanol) and extensively washed before measurement of 
fluorescence above 560 nm by flow cytometry or confocal microscopy (TCS2-




CD40L-stimulated CLL cells, either untreated or treated with 15 M ST1326 
for 24h, were washed with ice-cold PBS (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) and lysed in lysis buffer (20 mM Hepes, 150 mM NaCl, 
10% glycerol, 1% Triton X-100, 1 mM Na3VO4 and protease inhibitor (Sigma 
Chemical Co., St Louis, MO, USA)) for 20 min on ice. Lysates were centrifuged 
10 minutes at 10.000 g in a microfuge and supernatants collected. Protein 
concentration was assessed by the Bradford method. Samples were denaturated 
by the addition of Laemmli sample buffer 4x and were boiled for 5 min. 30 μg of 
total proteins were used for each sample and loaded onto a 10% sodium dodecyl 
sulfate–polyacrylamide gel (SDS-PAGE). Run was performed at 4°C, at 50 mA 
for each gel, for 120 min. Electrophoretically separated samples were transferred 
onto nitrocellulose (NC) membranes by electroblotting, at 400 mA, at 4°C for 90 
min. NC membranes were blocked: 1h in 1X PBS, 0.1% Tween® 20 with 5% 
w/v Bovine serum Albumine (BSA) for the phosphorylate proteins, and 1h in 
1X PBS, 0.1% Tween® 20 with 5% w/v nonfat dry milk for the total proteins; 
then the membranes were incubated, over-night at 4°C, with the specific primary 
antibodies (Abs): anti-Mcl-1 (Santa Cruz Inc, USA), anti-Bcl-xL (Santa Cruz 
Inc, USA), anti-phospho AKT (Cell Signaling Technology, USA), anti-AKT 
(pan) (Cell Signaling Technology, USA), anti-phospho-IkB (Cell Signaling 
Technology, USA), anti-IkB (pan) (Cell Signaling Technology, USA), anti-
NFKB (Cell Signaling Technology, USA), anti-phospho STAT3 (Tyr705) (Cell 
Signaling Technology, USA), anti-phospho STAT3 (Ser727) (Cell Signaling 
Technology, USA), anti-STAT3 (pan) (Cell Signaling Technology, USA), anti-
phospho STAT6 (Cell Signaling Technology, USA), anti-phospho JAK3 (Cell 
Signaling Technology, USA), anti-JAK3 (pan) (Cell Signaling Technology, 
USA), anti-phospho JAK2 (Cell Signaling Technology, USA), anti-JAK2 (pan) 
(Cell Signaling Technology, USA) and goat polyclonal anti-Actin (Santa Cruz 
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Inc. USA, sc-1616). Membranes were then washed for 5 times with 0.1% PBST 
(1X PBS, 0.1% Tween® 20) and incubated with secondary HPR-conjugated Abs 
(diluted at 1: 3000 for anti-mouse and 1:1000 for anti-rabbit) for 1h at RT. After 
extensive washing with 0.1% PBST, binding of Abs was revealed by an enhanced 
chemiluminescence detection system. Blots were acquired by using the 
instrument mini HD (Uvitec, Cambridge, UK). Each band was converted by mini 
HD into a densitometric trace allowing calculations of intensity and signals 
normalized on the signal of actin, used as the housekeeping protein, and also on 




Combination cytotoxicity of ST1326 and a second drug: Fludarabine, ABT-
199, Ibrutinib or Idelalisib, was calculated by the Chou-Talalay method (92) 
(CalcuSyn software, Biosoft, Cambridge) with the CalcuSyn software (Biosoft, 
Cambridge, UK). Combination index (CI) was computed from dose-effect 
curves of drugs alone and in combination. CI represents a measure of the effect 
of drug interaction (additive effect: 0.9 ≤ CI ≤ 1.1, synergism: CI < 0.9 and 
antagonism: CI > 1.1). CI depends on the ‘fractional effect level’ at which it is 
calculated. We considered two levels of cytotoxicity, LC75 and LC90 




For statistical comparison between samples, the Mann-Whitney U test was 
used for unpaired sample data and the Wilcoxon signed-rank test for paired 
sample data. Analyses were performed using the GraphPad Prism version 5.00 






Clinical and molecular characteristics of CLL patients  
 
Leukaemic cells derived ex-vivo from 26 patients with CLL were used to 
study the in vitro effects of ST1326 (Table 1). The cohort of patients is 
heterogeneous with regard to both disease stage and prognostic markers. It is 
noteworthy that several patients displayed unfavourable characteristics 
associated with poor prognosis and resistance to the current therapies. In 
particular, our cohort included 8/26 Binet C and 8/26 Binet B patients (Table 1). 
Likewise, patients with a more aggressive clinical behaviour included U-CLL 
cases (11/26), CD38+ CLL cases (16/26), CLL patients harbouring TP53 
mutations (2/26), SF3B1 mutations (1/26) and chromosomal aberrations, such as 




Table 1: CLL patient characteristics  
  
In vitro cytotoxic effect of ST1326 on stimulated CLL cells 
 
We first addressed the cytotoxic activity of ST1326 on leukaemic cells, both 
on quiescent and activated CLL cells. Cell activation was achieved by culturing 
primary CLL cells, at high cell density, in the presence of i) CD40L-expressing 
fibroblasts+IL-4 or IL-21, or ii) CpG ODN+IL-15, whose synergy is important 
TABLE S1 
 





§ U-CLL and M-CLL : <2% and ≥2% in IGHV difference from germline, respectively. 
§ n.d. not determined	
§ * 27%, ** 19%, *** 11%	
Pts
# 





VH gene TP53 NOTCH1 SF3B1 Chromosomal 
aberrations (FISH) 
1 C M-CLL POS VH3-30 wt wt wt del 11q22*, del 
13q14**, del 17p13*** 
2 B U-CLL POS VH1-69 wt wt wt nd 
3 C M-CLL POS VH3-7 nd wt nd nd 
4 C U-CLL POS VH3-48 nd wt wt nd 
5 B U-CLL NEG VH3-11 wt wt wt del 13q14 
6 B M-CLL POS VH4-31 wt wt wt nd 
7 C U-CLL POS VH5-51 nd wt wt nd 
8 A M-CLL NEG VH3-30 nd wt wt nd 
9 C U-CLL POS VH1-69 wt wt wt del 17p13, del 13q14, 
trisomy 12 
10 C U-CLL POS VH4-74 MUT wt wt del 11q22, del 13q14 
11 A M-CLL POS VH4-34 wt wt wt nd 
12 C M-CLL POS VH1-2*02 nd nd nd del 17p13 (5%) 
13 - U-CLL NEG VH1-
18*04 
wt nd nd NEG 
14 A U-CLL POS VH1-
69*01 
wt nd nd del 11q22, del 13q14, 
del 17p13 (5%) 
15 B M-CLL NEG VH4-
34*01 
wt nd wt trisomy 12 
16 A U-CLL NEG VH4-
39*01 
MUT nd wt trisomy 12 
17 A M-CLL POS VH3-
48*02 
wt nd nd del 13q14 
18 A M-CLL POS VH1-
18*01(FR
1)/JH4B 
wt nd nd del 11q22, del 13q14 
19 B M-CLL POS VH3-7*01 wt nd nd trisomy 12 
20 A M-CLL POS VH3-
72*01 
wt nd nd del 13q14 
21 B M-CLL NEG VH3-
48*02 
nd nd nd del 13q14 
22 B U-CLL NEG 3-23, 3-21 wt wt MUT  del 13q14 
23 A U-CLL POS VH4-
34*01 
wt nd nd trisomy 12, del 17p13 
24 C M-CLL NEG VH3-
72*01 
wt nd nd del 17p13, del 13q14 
25 - M-CLL NEG VH3-7*03 wt nd nd  del 11q22, del 13q14 
26 B M-CLL NEG VH3-
23*01 
wt nd nd del13q14 
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to promote CLL cells clonal expansion (89; 90), in the presence, or not, of 
BMSC.  
The response to microenvironment mimicking stimuli was followed by 
monitoring cellular parameters associated with CLL activation phenotype and 
increased in cell size (forward light scattering) (not shown). ST1326 was added 
at the beginning of the stimulation.  
Multiparameter flow cytometry was used to measure cell death (damage of 
cell plasma membrane by PI uptake) and loss of mitochondrial transmembrane 
potential (decreased fluorescence of the cationic voltage-dependent fluorescent 
probe DiOC6). 
We observed a significant decrease in the viability of in vitro stimulated CLL 
cells compared to quiescent ones (Figures 1A, B). Cell death was preceded by 
mitochondrial transmembrane potential (ΔΨ) dissipation, as demonstrated by 
ST1326-induced ΔΨ decrease observed in cells with an intact plasma membrane 






















Figure 1- Sensitivity to ST1326 of quiescent and activated/proliferating CLL cells.  
A) Cell viability assessed by flow cytometric PI exclusion tests on quiescent or CD40L-stimulated cultures 
of leukaemic cells from 26 independent CLL patients untreated or treated with ST1326 (48 hours). Cell 
activation was achieved either through CD40L-NIH-3T3+IL-4 (number of independent experiments n=22) 
or IL-21 (n=4), or by CpG/ODN2006+IL-15, in the absence (n=7) and the presence (n=3) of BMSC. Mean 
(± range) of 10 μM ST1326-induced viability reduction (% control) were: 64.8±(23-94), 56.5 (50-70), 68 
(48-88) and 61 (55-72), for the four different activation systems, respectively. Statistical significance of the 
difference is evaluated by two-sided Wilcoxon signed rank test. *p 0.05; **p 0.01; ***p 0.001;***p 
0.001;****p 0.0001. B) Flow cytometric bivariate plots of ΔΨ as measured by DiOC6 fluorescence, and 
cell viability, as assessed by PI fluorescence, of leukaemic cells from one representative CLL patient. Cells 
were non-stimulated or stimulated either with CD40L-NIH-3T3+IL-4 or CpG+IL-15 (in this sample also in 
the presence of BMSC), and exposed to ST1326 for the times indicated. All controls were measured 48 
hours after culture start. Events in the dotted gate are cells with functional ΔΨ and intact plasma membrane. 
This CLL patient harbors 17p13 deletion. C) ΔΨ gated on the vital cell population, as measured by DiOC6 
uptake and expressed as flow cytometric fluorescence intensity (MFI) of the PI-excluding cell population 
(with intact plasma membrane), on quiescent or CD40L-stimulated cultures of leukaemic cells from 26 CLL 
patients untreated or treated with ST1326 from the beginning of stimulation (48 hours). Number of samples 
for each condition is indicated. Statistical significance of the difference is analysed by t-test two- sided 
Wilcoxon signed rank test. *p 0.05; **p 0.01; ***p 0.001; ***p 0.001; ****p 0.0001.   




































































































































































































































































































































Sensitivity to ST1326 of quiescent and activated/proliferating CLL cells. 
Flow cytometric bivariate plots of mitochondrial transmembrane potential (ΔΨ ) as measured by 
DiOC6 fluorescence, and cell viability, as assessed by PI fluorescence, of leukemic cells from one 
representative CLL patient. Cells were non-stimulated or stimulated either with CD40L-expressing 
fibroblasts+IL-4 or CpG+IL-15 (in this sample also in the presence of bone marrow stromal cells, 
BMSC), and exposed to ST1326 for the times indicated. In stimulated cell cultures, the drug was 
added at the beginning of stimulation. All controls were measured 48 hours after culture start. 
Events in the dotted gate are cells with functional ΔΨ  and intact plasma membrane. This CLL 




Notably, ST1326 was effective independently from stimulation and even 
when proliferation was induced in the presence of BMSC (Figures 1A, B), known 
to provide a protective microenvironment. Furthermore, the CPT1A inhibitor 
showed to be effective also in CLL samples harbouring mutated TP53, mutated 
SF3B1 or chromosomal abnormalities, known to confer chemoresistance (Table 
1 and Figure 1B).  
Interestingly, cytotoxicity was achieved at drug concentrations 10 times 
lower than concentrations needed for the more common CPT1 inhibitor Etomoxir 
to reach similar effects (Figure 2).  
 
 
Figure 2- Etomoxir is cytotoxic in vitro at ten times higher molarity if compared to ST1326.  
Left: Cell viability assessed flow cytometrically PI exclusion tests on CD40L+IL4-stimulated cultures of 
leukaemic cells from 4 CLL patients untreated or treated with Etomoxir (48 hours). Right: Mitochondrial 
transmembrane potential (ΔΨ) gated on the vital cell population, as measured by DiOC6 uptake and 
expressed as flow cytometric fluorescence intensity (MFI) of the PI-excluding cell population (with intact 
plasma membrane), on same sample as ‘left’. 
 
Proliferating/activated CLL cells are more sensitive to ST1326 
treatment 
 
In order to deepen the understanding of the differential effect of ST1326 on 
quiescent and proliferating/activated CLL cells, we analysed the subpopulation 
of i) activated/proliferating cells, ii) quiescent cells and iii) death cells, within the 
same sample. In particular, we compared the percentage of the cells present in 
these areas between the control and treated sample. 
We were able to discriminate the live cells from the dead cells by staining 
with PI, which is not able to cross the cell membrane and is therefore taken up 
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only by dead cells (data not shown). In order to distinguish the quiescent cells 
from the activated ones, we relied on morphological aspects; resting cells are 
characterized by a lower front scatter value compared to the 
activated/proliferating cells (data not shown). 
Comparing over the course of the days the percentage of cells present in each 
compartment, in the control (stimulated cells) and in the treated cells (stimulated 
in the presence of ST1326), we observed a reduction in the percentage of cells 
present in the quiescent compartment with a similar trend between control and 
treated cells. Instead, if we consider the population of activated cells, after an 
initial increase in the percentage of cells present in this compartment, there is a 
sharp reduction only in the case of the treated sample. In conjunction to this 
depletion in the treated sample, an increase of death cell fraction was observed, 
suggesting that dead cells arose preferentially from the activated compartment 
rather than from the quiescent one (Figure 3). 
Figure 3- Intra-patient analysis: differential effect of ST1326 on quiescent and activated/proliferating CLL 
cell compartment. 
CLL cells from one patient stimulated with fibroblast-CD40L+IL-4 and treated, or not, with ST1326 10 µΜ, 
were analyzed with flow cytometry for the determination of cells size and cell mortality by using the PI 
exclusion assay. The graph on the right shows the analysis of the percentage of cells present in the quiescent, 
activated/proliferating and death area during the days. ‘CPT1A-inhib’ indicates ST1326. 
We focused on this behaviour by KI67/DNA measurements. KI67 expression 
rose after stimulation in a fraction of CLL cells, as expected (Figure 4 left). 
However, the presence of ST1326 induced the disappearance of KI67+ cells and 
the concomitant increase of sub-G1 events (Figure 4 left), indicating that cycling 
cells were more sensitive to ST1326 than quiescent ones. Results of overall KI67 
expression are displayed for 8 CLL patients (Figure 4 right). 































Figure 4- ST1326 determines a reduction in the percentage of Ki-67 positive cells and an increase in the 
cells present in the sub-G1 compartment. 
Left: Flow cytometric distributions of DNA content/KI67 expression for one representative CLL sample. The 
CD40L-stimulated cells were tested in the absence or presence of ST1326. Gates identify KI67+ cells (above 
the negative-threshold dotted line) and sub-G1 events (apoptotic cells and bodies, below). Right: %KI-67-
positive cells from CLL samples of eight CLL patients, tested with or without addition of ST1326.  
 
Taken together, these results confirm the observation that activated and/or 
proliferating CLL cells are more sensitive to ST1326 than quiescent ones. 
The proof of the different sensitivity of the non-stimulated and stimulated 
cell cultures came also from the observation that a 40-hours pulse of ST1326 
given at later stages after stimulation (i.e. when the cells already express 
activation markers and start progressing through the G1/S checkpoint) was more 
cytotoxic than when drug was administered at the beginning of stimulation. This 
is at variance with other drugs (Fludarabine and ABT-199) that lost their 
effectiveness if added to overtly activated CLL cells (Figure 5).  
































































































































































ST1326 cytotoxicity effect correlates with the in vitro proliferative 
response to activation stimuli 
 
We analyzed the correlation between the cytotoxic response to the drug and 
i) clinical parameters (Binet disease stage), ii) molecular parameters  (mutational 
status of the variable region of the IGV immunoglobulin and expression of 
CD38) or iii) in vitro cellular parameters (proliferative potential).  
We found a strong relationship of ST1326 cytotoxicity with the in vitro CLL 
proliferative response to activation stimulus (Figure 6), which further 
corroborates the notion that CLL cells in an activated/proliferating state are more 
sensitive to the inhibition of CPT1A compared to the quiescent ones.  
Conversely, cytotoxicity was apparently independent from all other clinical and 









Figure 5- Increased sensitivity to ST1326 in CLL cells that are in advanced stages of their activation. 
Cell viability in cells from two CLL patients exposed to a 40-hours drug ‘pulse’, either concomitantly with 
CD40L-stimulation (T0) or after 48-hours (T48). The different ST1326 sensitivity of CLL cells at T0 or T48 
is evident. In contrast, the effect of Fludarabine (10 μM) and ABT-199 (5 nM) was remarkably impaired if 
the cells were exposed to the drugs at T48.  


































































































































































Figure 6- Correlation between cytotoxic effect of ST1326 and in vitro proliferative response to 
microenvironment stimuli. 
Effect of ST1326 on average cell viability of CD40L-stimulated CLL cells. The 26 patients were grouped 
according to disease stage (Binet A, B or C), Ig mutational status (U-CLL, <2% mutations in IGVH) and 
mutated (M-CLL, 2% mutations in IGVH genes), proliferative response to CD40L-stimulation (‘low’ or 
‘high’ if  % cells in S+G2M cell cycle phase after 72h stimulation was  or  8%, respectively), and CD38 
expression (cut-off: 30%). Statistical significance of the difference is assessed by two-sided Mann-Whitney 
test. The difference is not significant where no indication is reported. *p 0.05; **p 0.01; ***p 0.001; ***p 
0.001; ****p 0.0001.  
CLL cells are more sensitive to ST1326 than healthy peripheral blood 
lymphocytes 
 
We explored a possible therapeutic window between CLL cells and normal 
B lymphocytes. To this end, experiments on purified B cells obtained from the 
peripheral blood of healthy donors, activated by CD40L-expressing 
fibroblasts+IL-4, were conducted. The response to the stimulation was followed 
by monitoring cellular parameters associated with B activation phenotype and 
increased in cell size (forward light scattering) (not shown). ST1326 was added 
simultaneously to the activating stimuli. 
 We found that normal B lymphocytes were less sensitive to ST1326 
cytotoxicity, at the doses lethal for CLL cells (Figure 7 for CD40L+IL-4 
stimulated B cells, not shown for unstimulated B cells). Instead, cell proliferation 
was partly inhibited, indicating a cytostatic, rather than cytotoxic, effect of 
ST1326 on normal B cells (Figure 7).  



































































































































































Figure 7- Healthy peripheral blood lymphocytes show a partly inhibition of cell proliferation after the 
treatment with ST1326.  
Normal B cells from healthy volunteers were purified by magnetic beads (negative selection), activated by 
co-culturing with CD40L+IL-4 and treated for 48h with 10 M ST1326. Cell death and proliferation were 
measured by flow cytometry. Viability was unaffected, while cell proliferation (% cells in S+G2M phase) 
is reduced in two samples.  
 
ST1326 cytotoxicity was associated with decreased levels of 
intracellular Acetyl-CoA  
 
Important for cell proliferation is the production of the Acetyl-CoA (93), 
generated by the degradation of FAs via β-oxidation. Since the CPT1A inhibitor 
prevents the entry of FAs into the mitochondria, we decided to verify if the 
treatment with ST1326 causes a reduction in Acetyl-CoA production.  
We stimulated the CLL cells for 24 hours, a sufficient time in order to induce 
the cells to become activated blasts, and then we added ST1326. We decided to 
add drugs after 24 hours of stimulation because the treatment with ST1326 is 
stronger when it is administered at the beginning of stimulation, as demonstrated 
before. We measured the cytoplasmic level of Acetyl-CoA at different time 
points (0, 8, 15, 24, 30 hours) after the treatments. As a positive control, 2-Deoxy-























































































































































































































D-glucose (2-DG) was used. 2-DG is a stable glucose analogue that is actively 
taken up by the hexose transporters and phosphorylated, but it cannot be fully 
metabolized (94). The treatment with 2-DG decreases the amount of substrates 
available for aerobic respiration and, as a result, this causes a reduction in Acetyl-
CoA production.  
We observed that the administration of ST1326 decreased intracellular levels 
of Acetyl-CoA already after 15 hours of treatment (Figure 8), further 
corroborating the notion that ST1326 is able to block the degradation of FAs in 
mitochondria, thus reducing the production of Acetyl-CoA.  
Figure 8- Effect of ST1326 on Acetyl-CoA production. 
Acetyl-CoA levels in leukemic cells from one CLL patient stimulated for 24 hours and then exposed to ST1326 
(10 M) or 2-DG (5 mM). Data obtained by colorimetric tests using the PicoProbe Acetyl-CoA Assay Kit, are 
reported as mean ± SD of three experiments (two settings with CpG- and one with CD40L-stimulus). The 
levels of intracellular Acetyl-CoA increase during CLL cell activation, and ST1326 affects the increase rate. 
2-DG was used as control. *p 0.05; **p 0.01; ***p 0.001; ***p 0.001; ****p 0.0001. 
 
Stimulated CLL cells die by apoptosis after ST1326 treatment  
 
We verified if the treatment with ST1326 causes apoptotic cell death in 
stimulated CLL cells, by using an Annexin V+PI labelling. Annexin V is a 
protein that binds phosphatidylserines, which are normally found in the inner 
membrane but become flipped to the outer during the early stages of apoptosis. 
Cells that are positive for Annexin V and negative for PI are defined as early 
apoptotic cells while cells that are positive for both Annexin V and PI are 
defined as late apoptotic cells. 


































































































































































We observed that ST1326 determined an increase in the percentage of 
activated cells that undergo apoptosis (Figure 9). The percentage of Annexin V-
positive cells was reduced when ST1326 was administered together with L-
carnitine and oleic acid (Figure 9). This is in line with described target 
competition of the drug (86), and possibly due to fatty acid-promoted activation 
of PPAR- that in turn upregulates CPT1A (95), thus counteracting the cytotoxic 
effects of ST1326. 
Figure 9- Cytotoxic effect of ST1326 in the absence and presence of oleic acid + carnitine. 
Annexin V-FITC/PI cytometric distributions of one CLL CD40L stimulated sample, untreated or treated 
with ST1326 (± oleic acid (300 μM)/BSA (50 μM) + L-carnitine (100 μM) for 48h and 72h. The graph shows 
the percentage of AnnexinVneg cells (viable cells), AnnexinVpos / PIneg (early apoptotic cells) and 
AnnexinVpos / PIpos (dead cells). 
   
Apoptosis of ST1326-treated CLL cells was associated with Bax 
activation and intracellular accumulation of lipids 
 
One of the most important executors of apoptosis is represented by the 
activated form of Bax. After various type of apoptotic-stimuli, Bax triggers the 
apoptotic cascade by inducing the release of cytochrome c from mitochondria 
(31; 63). 
We evaluated by flow cytometric analysis the expression of the activated 
form of Bax by specific antibody, after ST1326 treatment of both proliferating 
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CLL cells and proliferating normal B lymphocytes. We observed a strong 
increase, in a time-dependent manner, in the expression of active-Bax in 
proliferating CLL cells (Figure 10A). On the contrary, proliferating normal B 
lymphocytes showed only a slight increase in the expression of active-Bax 
(Figure 10A). This confirms that normal B lymphocytes, at the doses lethal for 
CLL cells, were less sensitive to ST1326 cytotoxicity. 
 
By blocking CPT1A, ST1326 treatment prevents the entry of FAs into the 
mitochondria. One consequence of this blocking may be an intracellular 
accumulation of lipids that, in virtue of their detergent properties, may induce 
Bax activation (85). Experiments with Oil red O (ORO) staining, which binds 
neutral triglycerides and lipids, showed ST1326-mediated intracellular 
accumulation of lipids (Figure 10B), which was in part inhibited by 
supplementation of L-carnitine (Figure 10B). 
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Figure 10- ST1326 induces Bax activation and intracellular accumulation of lipids that is impaired by 
exogenous L-carnitine.  
A) Left: Flow cytometric distributions of Forward Light Scatter (FSC)/active-Bax expression, of 
CD40L+IL-4-stimulated B lymphocytes from one CLL patient and one healthy donor, untreated or treated 
with ST1326 for the reported times. The percentage of cells expressing the active form of Bax (recognized 
by the 6A7 antibody) is indicated. Right: data from CLL samples of three CLL patients. B) Upper: Confocal 
microscopy images of CLL cells stimulated with CD40L+IL-4-fibroblasts in the absence (left) or presence 
of ST1326 (10 μM, 48 hours), without (middle) or with L-carnitine addition (100 μM). Intracellular neutral 
triglycerides and lipids are in red (Oil Red O staining) and nuclei in blue (DAPI staining). Lower: 
intracellular lipid levels as evaluated by fluorescence intensity of Oil Red O-stained cells from two CLL 
patients. Stimulated CLL cells displayed lower intracellular lipid levels than quiescent cells, possibly 
reflecting the fatty acid use for de novo membrane synthesis during proliferation.  
Figure S4 
               
 
Figure S4 
ST1326 induces Bax activ tion and intracellular accumulation of lipids that is impaired by 
exogenous L-carnitine. 
A) Left: Flow cytometric distributions of Forward ight Scatter (FSC)/active-Bax expression, 
of CD40L+IL-4-stimulated B lymphocytes from one CLL patient and one healthy donor, 
untreated or treated with  ST1326 for the reported times. The perce tage of cells expressing the 
active form of Bax (recognized by the 6A7 antibody) is indicated. Right: data from CLL samples 
of three CLL patients. 
B) Upper: Confocal microscopy images of CLL cells stimulated with CD40L+IL-4-fibroblasts in 
the absence (left) or presence of ST1326 (10 μM, 48 hours), without (middle) or with L-carnitine 
addition (100 μM). Intracellular neutral tryglycerides and lipids are in red (Oil Red O staining) 
and nuclei in blue (DAPI staining). Lower: intracellular lipid levels as evaluated by fluorescence 
intensity of Oil Red O-stained cells from two CLL patients. Stimulated CLL cells displayed 
lower intracellular lipid levels than quiescent cells, possibly reflecting the fatty acid use for de 
novo membrane synthesis during proliferation.  
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ST1326 impairs stimulation-induced activation of Mcl-1 and Bcl-xL 
in CLL cells  
 
The Bcl-2 family members are key regulators of the intrinsic apoptotic 
pathway. Especially relevant are Mcl-1 (45) and Bcl-xL (44), that are associated 
with high risk of CLL disease progression and poor response to chemotherapeutic 
agents and BH-3 mimetics treatment (46; 72; 73). We investigated the effect of 
ST1326 on the expression of these two important anti-apoptotic proteins.  
Flow cytometric immunofluorescence measurements and western blots were 
performed altogether on 14 samples from 7 different CLL patients, stimulated 
with CD40L+IL-4 or quiescent (the latter only in the case of 
immunofluorescence). The results indicated, in all samples, a consistent decrease 
of both anti-apoptotic proteins expression after 24 hours of treatment with 
ST1326 (Figure 11), when overt cell death is not observed yet. Also, the analysis 
was performed on viable cells only (as defined by flow cytometric scatter 
signals). Thus, reduction of anti-apoptotic protein expression anticipated cell 
death and is not due to cell death-associated proteolytic mechanisms. 
Figure 11- ST1326 impairs stimulus-induced Mcl-1 and Bcl-xL up-regulation.  
Left: Expression of the Bcl-2-family anti-apoptotic members Mcl-1 and Bcl-xL, in leukaemic cells from 4 
CLL patients, stimulated with CD40L+IL-4, and treated with or without ST1326 24 hours after stimulation.  
Middle: Cumulative data for 24 and 42 hours treatment are represented in the box/whiskers graph (5-95 
percentile), where protein level in ST1326-treated samples (divided by housekeeper) is calculated as % 
untreated controls.  
Right: Protein expression evaluated by intracellular immunofluorescence and flow cytometry (background-
subtracted fluorescence) on samples from 5 CLL patients is reported as cumulative graph. Quiescent (Q= 
non-stimulated), stimulated (Act) in the absence or presence of ST1326. Non-parametric t-test was used to 





ST1326 impairs stimulation-induced activation of STAT3 and STAT6 
in CLL cells  
 
In CLL, Mcl-1 and Bcl-xL expression are under the control of signalling 
pathways that include AKT (96), NF-KB/STAT3 (97) and STAT6 (98).  
Transcription factors STAT3, NF-KB and AKT are aberrantly activated in 
many cancer cells. These tumour-associated transcription factors co-regulate 
gene expression, resulting in significant upregulation of genes involved in 
tumour cell survival, proliferation and immunosuppression. Specifically in CLL 
cells, NF-KB is activated also by the unphosphorylated form of STAT-3 (99), 
which is highly expressed in CLL cells (100). STAT3 exhibits the peculiarity of 
being activated not only through the more common (Tyr705)-phosphorylation 
but also through the phosphorylation on Ser727, which is constitutively 
phosphorylated in CLL cells (100). 
Accordingly, we analysed by western blot the effects of ST1326 on the 
expression of Akt (pan), IkB (pan), NF-KB (pan), JAK3 (pan), JAK2 (pan), 
STAT3 (pan), and the phosphorylated forms: p-STAT3 (Tyr705), p-STAT3 
(Ser727), p-STAT6, p-JAK3, p-JAK2, p-Akt, and p-IkB. Only NF-KB (pan), 
STAT3 (pan), p-STAT3 (Tyr705) and p-STAT3 (Ser727) were analysed also by 
flow cytometry. 
AKT did not display a decrease pattern similar to Mcl-1/Bcl-xL. Its 
phosphorylation was only mildly decreased (Figure 12), in spite of marked Mcl-
1/Bcl-xL reduction. Likewise, no clear-cut association was evident between the 
drop of anti-apoptotic proteins expression and NF-KB modulation, as indicated 
by the expression of NF-KB regulators p-IKBα/IKBα, and by cytoplasmic (WB) 
and nuclear (flow cytometry) NF-KB levels (Figure 12). The changes of NF-KB 
expression in the nucleus after ST1326 treatment were very variable across 
patients (Figure 12) and did not correlate with Mcl-1/Bcl-xL drop intensity or 
with apoptotic response to the drug. 
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Figure 12- Effects of ST1326 on AKT and NF-kB activity.  
Left: Western blots of total and phosphorylated (p) AKT (Ser473) and IKBα (Ser32/36) and NF-kB 
(RelA/p65) in 4 CLL cell samples stimulated with CD40L+IL-4 for 1 day and treated with ST1326 for 
another 24 hours. Different signalling pathways were examined in parallel gels and blots were stripped and 
re-probed with the indicated antibodies.  
Right upper panel: Cumulative data calculated as in figure 11. Statistical significance of the difference is 
analysed by non-parametric t-test. *p 0.05; **p 0.01; ***p 0.001;****p 0.0001.  
Right lower panel: NF-kB (RelA/p65) expression in isolated nuclei from CLL cells treated in culture as 
above, stained with anti-NF-kB (RelA/p65) antibody and measured by flow cytometry. Cells were non-
stimulated (Q), CD40L+IL-4 stimulated without (A) or with ST1326 (A+ST). Dexamethasone (DEX) 
treatment for 24 hours (100 nM) was used as positive control for NF-kB down-regulation.  
Instead, STAT3 phosphorylation was profoundly affected by ST1326 
(Figure 13). Expression of both phospho (Tyr705)- and phospho (Ser727)-
STAT3, displayed substantial reduction, observed well before overt apoptosis 
(Figure 13). Interestingly, total STAT3 (U-STAT3) expression was diminished 
as well. Also, STAT6 phosphorylation was remarkably reduced after treatment 






Figure 13- ST1326 induces remarkable STAT3 and STAT6 down-regulation. 
Left: Western blots of STAT3 (pan) and its phosphorylated forms pSTAT3(Tyr705) and pSTAT3(Ser727), 
of total and phosphorylated JAK2 (Tyr1008) and JAK3 (Tyr980/981), and pSTAT6, in leukaemic cells from 
4 CLL patients stimulated with CD40L+IL-4 for 1 day and treated with ST1326 for another 24 hours. 
Different signalling pathways were examined in parallel gels and blots were stripped and re-probed with the 
indicated antibodies.  
Middle: Cumulative data for STAT3 are calculated from western blots of 8 samples from 6 CLL patients: 
the average ratio of STAT3 (unphosphorylated, phospho-Tyr705 and phospho-Ser727 STAT3) versus either 
unphosphorylated protein level or the housekeeper are displayed as relative decrease of protein levels in 
ST1326-treated compared to untreated samples (set to 100). Cumulative data for JAK2 and JAK3 are 
calculated from 4 CLL patients. Non-parametric t-test was used to assess statistical significance of the 
difference. *p 0.05; **p 0.01; ***p 0.001; ****p 0.0001.  
Right: expression of STAT3 and its phosphorylated forms as evaluated by intracellular immunofluorescence 
and flow cytometry on leukemic cells from 5 CLL patients, either non-stimulated (Q) or stimulated (Activ.) 
in the absence or presence of ST1326 (24-30 hours). Importantly, background-subtracted data are restricted 
to viable cells.  
 
In the face of the striking reduction of STAT3 and STAT6 phosphorylation 
in all CLL patients, the phosphorylation of JAK2 and JAK3, which are involved 




Combination cytotoxicity of ST1326 with ABT-199  
 
ABT-199 (Venetoclax) is a promising BH3 mimetic that shows a selective 
affinity for Bcl-2. However, due to its selectivity for Bcl-2, ABT-199 has limited 
efficacy when Bcl-xL and Mcl-1 are overexpressed, which is the case of 
proliferating CLL cells (72; 73). Accordingly, we explored whether resistance to 
the BH3-mimetic could be overcome by ST1326 that down-regulates Bcl-xL and 
Mcl-1 in stimulated CLL cells. 
Combined cytotoxicity of ST1326 administered together with other drugs 
was calculated by the Chou–Talalay method (103). This method is based on 
physico-chemical algorithms of the mass-action law, specifically with the unified 
theory of the median-effect equation and its combination index theorem for drug 
combinations (92).  
The activated/proliferating CLL cells are much more resistant to ABT-199 
than quiescent cells are (72). Thus, CD40L-stimulated CLL cell cultures were 
treated in our dose-response experiments with 10-fold higher doses of ABT-199 
compared to unstimulated CLL cell cultures (that is, 5 or 50 nM for unstimulated 
or stimulated CLL cells, respectively). We observed that the co-administration 
of ST1326 with ABT-199 significantly increased the cytotoxicity of sub-lethal 









































































































































Figure 14- Synergic ST1326 and ABT-199 drug 
combination in activated CLL cells. 
Left: Upper: Flow cytometric bivariate plots of  
(DiOC6 fluorescence) and cell viability (PI exclusion) 
of leukaemic cells from one representative CLL patient 
stimulated with CD40L+IL-4 and cultured with ST1326 
(10 M), ABT-199 (10 nM), or both drugs for 42 hours. 
Middle: ST1326 and/or ABT-199 cytotoxicity (42h) on 
unstimulated (Quiescent) and CD40L-stimulated 
(Activated) CLL cultures. Only stimulated CLL cells 
displayed increased sensitivity to drug combinations, if 
compared to either drug alone. Lower: CI values (at 
LC75 and LC90) calculated by the Chou–Talalay model 
on dose-effect profiles of activated CLL cells treated for 
24 hours with increasing concentrations of ST1326 (1–
10 M), ABT- 199 (10–100 nM) or ST1326/ABT-199 
at constant ratios. Since CI depends on the ‘fractional 
effect level’, we report two levels of cytotoxicity, LC75 
and LC90 (concentration lethal to 75% and 90% of CLL 
cells). Dotted lines indicate CI=0.9 and CI=1.1 
Synergism =CI<0.9, additive effect = 0.9CI 1.1 and 
antagonism = CI>1.1.  
Right: CI curves and isobolograms. For each patient one 
CI and isobologram from one representative experiment 
are shown. Isobolograms: additive: point on the line, 
synergism: point below the line, antagonism: point 
above the line.  
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Since the combination effect also depends on the ‘fractional effect level’ at 
which it is calculated, we considered two levels of cytotoxicity, LC75 and LC90 
(concentration lethal to 75% and 90% of CLL cells). CI values and isobolograms 
demonstrate a ‘more-than-additive’ effect for ST1326/ABT-199 drug 
combination (Figures 14 lower and right).  
 
Combination cytotoxicity of ST1326 with Fludarabine  
 
Fludarabine is a chemotherapeutic agent with a remarkable activity in B-CLL 
(41), whose cytotoxicity is hampered by high expression of Mcl-1 and Bcl-xL 
(45; 46). Our drug combination experiments showed that the combined treatment 
of CLL cells with Fludarabine and ST1326 induced higher cytotoxicity if 
compared to each drug alone in activated conditions (Figure 15 upper). 
  
Figure 15- Synergic ST1326 and Fludarabine drug combination in activated CLL cells.  
Left: Upper: Combination cytotoxicity of ST1326 (5 M) and Fludarabine (10 M), administered for 24 
hours to activated CLL samples. Lower: CI values (at LC75 and LC90) calculated by the Chou–Talalay 
model on dose-effect profiles of activated CLL cells treated for 24 hours with increasing concentrations of 
ST1326 (1–20 M), Fludarabine (1–30 M) or ST1326/Fludarabine at constant ratios.  
Right: CI curves and isobolograms. For each patient, CI and isobologram from one representative 
experiment are shown, at LC75 and LC90 level of cytotoxicity. 
 



















































In particular, isobolograms and CI calculated from cytotoxicity profiles 
showed a remarkable level of synergy for ST1326/Fludarabine, in most CLL 
samples (Figures 15 lower and right). 
 
Combination cytotoxicity of ST1326 with Idelalisib and Ibrutinib  
 
A major advancement in therapy for CLL has been the development of two 
BCR signalling inhibitors: Ibrutinib and Idelalisib. However, recent data have 
reported the development of resistances to Ibrutinib (59; 60),  and the need to 
reduce the Idelalisib treatment dose due to relevant adverse events (61). 
Therefore, it would be interesting to evaluate if the combined treatment of these 
drugs with ST1326, can improve their efficacy. 
Data from drugs combination experiments showed that ST1326 did not 
potentiate the effects of either Ibrutinib or Idelalisib (Figure 16).  
 
Figure 16- ST1326 did not potentiated the effects of Ibrutinib or Idelalisib. 
Combination cytotoxicity of ST1326 (5 M) and Ibrutinib (5 M) or Idelalisib (5 M) administered for 24 
hours to activated CLL samples.   

















































































































































Discussion     
 
Is becoming increasingly clear that lipid metabolism has a crucial role in 
cancer cells. A recent study showed that CLL cells display an altered lipid 
metabolism if compared to normal B lymphocytes (74). In particular, the 
leukaemic cells show an up-regulation of factors involved in FAs metabolism 
such as LPL, CPT1A and PPAR- (74). Thus, lipid metabolism can represent 
another important source of energy, in addition to glucose metabolism, able to 
satisfy the energetic needs of proliferating leukaemic cells. ST1326 is a 
therapeutic agent that acts by blocking FAO metabolism, through the reversible 
and selective inhibition of CPT1A (86; 87), the rate-limiting enzyme of FAO.  
In this study, we addressed the in vitro effects of ST1326 on CLL cells either 
quiescent or stimulated to become activated blasts that enter the cell cycle.  
We demonstrated, for the first time, that ST1326 exerts in vitro, at doses that 
are clinically achievable, a remarkable apoptotic activity towards activated and 
proliferating CLL cells, irrespective of p53/SF3B1 mutational status or 
chromosomal aberrations, known to confer chemoresistance. Interestingly, 
normal B lymphocytes were more resistant to the cytotoxic activity of the drug. 
At the doses that are lethal to CLL cells, no cytotoxic, though slightly cytostatic, 
effect of ST1326 was observed.  
The cytotoxic effects of ST1326 in CLL cells were associated with a 
reduction of intracellular Acetyl-CoA levels and the downregulation of signalling 
pathways that are crucial for survival, activation and proliferation of leukaemic 
cells.  In particular, a reduction in Mcl-1 and Bcl-xL expression after ST1326 
treatment accounted for the potentiation of Venetoclax and Fludarabine, whose 
cytotoxic efficacy is hindered when cells enter proliferation and upregulate 
expression of anti-apoptotic proteins. These data indicate that FAO inhibition 
could represent a suitable target for CLL treatment.   
 
Treatment of CLL cells with ST1326 induced dose-dependent decrease of 
cell viability. Our results are in line with data previously reported by Pacilli et 
al., which demonstrated a potent cytotoxic effect of ST1326 on Burkitt’s 
lymphoma cells (81). As well, Ricciardi et al. showed a cytotoxic activity of 
ST1326 on leukaemia cell lines and primary hematopoietic malignant cells, 
including cells from CLL patients  (83). However, Ricciardi et al. did not evaluate 
the case in which the CLL cells are subjected to activating microenvironment-
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mimicking stimuli. In our experimental setting, we administered ST1326 also on 
stimulated CLL cultures and we demonstrated, for the first time, that 
activated/proliferating CLL cells are more sensitive to ST1326 treatment than 
quiescent ones. This is a very important result because these cells significantly 
contribute to CLL disease progression.     
 
We found that ST1326 treatment determined a reduction in the levels of 
intracellular Acetyl-CoA. The depletion of cytosolic Acetyl-CoA may be a 
consequence of CPT1A-blocking activity of ST1326 (81; 86; 87). In addition, it 
has been demonstrated, in a work by Pacilli et al., that ST1326 is able to inhibit 
also the activity of CACT (81), an enzyme responsible for the transport of acetyl-
carnitine in the cytoplasm, where it regenerates Acetyl-CoA and carnitine. As a 
consequence, also the inhibition of CACT causes a reduction in the intracellular 
level of Acetyl-CoA. Finally, given that Acetyl-CoA is also required for de novo 
synthesis of FAs, needed for the formation of new membranes, its reduction 
could result in a decrease of FAs production, which are very important for 
proliferating cells (93). Altogether, we may hypothesize that the depletion of 
cytosolic Acetyl-CoA induces a cellular energetic downturn that might account 
for the growth inhibition effects of ST1326.  
    
We observed an intracellular accumulation of lipid that is probably due to 
the CPT1A-blocking activity (86; 87), in line with previous observations on 
lymphoma and leukaemia cell lines (81; 83). This could account for the observed 
ST1326-induced activation of Bax if we consider the detergent properties of the 
accumulated lipids (85).  
 
The results of the present study showed that CPT1A inhibitor strongly affects 
STAT3 and STAT6 activation in stimulated CLL cells independently, at least in 
part, from the modulation of JAK2/3 and NF-KB. Interestingly, STAT3 total 
expression was diminished as well after ST1326 administration, probably 
because its expression is also regulated by p-STAT3 (100; 101). It remains to be 
elucidated how this drug down-regulates STAT3 and STAT6 activity. It is 
important to stress that STATs have a crucial role in CLL pathogenesis (99; 100). 




Peripheral blood B lymphocytes from healthy donors, were less sensitive to 
the cytotoxic effect of ST1326, at the doses that were effective on CLL cells, in 
line with the previous observation of no cytotoxic effect of ST1326 on normal 
bone marrow CD34+ cells (83). Instead, we observed a cytostatic effect after the 
treatment with the CPT1A inhibitor.  
We hypothesized that higher cytotoxicity of ST1326 in CLL cells may be 
due to the observation that cancer cells appear to be more addicted to the 
protective activity of Bcl-2 anti-apoptotic members compared to normal cells, 
possibly because these anti-apoptotic proteins have allowed the tumour cells to 
survive to deadly insults such as genomic instability, oncogene activation and 
cell cycle checkpoint violation (63).  
  
Induction of cell death was associated with the down-modulation of Mcl-1 
and Bcl-xL expression, two important anti-apoptotic proteins for CLL cells (44; 
45), that are correlated with the development of resistance against current 
therapies (45; 46; 72).  
In particular, the cytotoxic activity of the Bcl-2 selective inhibitor ABT-199 
(64), a novel promising antileukaemic agent, is impaired when Mcl-1 and Bcl-
xL are overexpressed (72; 73). In our experimental setting ST1326 potentiated 
the action of ABT-199 in stimulated CLL cells, and the combination of the two 
drugs turned out to be synergic.  
Another considerable clinical problem in CLL is the development of 
resistance against Fludarabine (16; 43; 45; 46). ST1326, by reducing Mcl-1 and 
Bcl-xL expression, could make proliferating CLL cells more sensitive to this 
chemotherapeutic agent. Our results demonstrated that ST1326 shows a 
synergic effect with Fludarabine in stimulated CLL cells.  
Finally, we evaluated the combination of ST1326 with novel BCR inhibitors: 
Ibrutinib and Idelalisib. Also in this case, chemoresistance and systemic side 
effects advocate therapies capable of reducing the administered dose (59; 60; 61). 
Our results show that ST1326 did not potentiate the effects of both drugs. A 
possible explanation could be that Ibrutinib and Idelalisib inhibit proliferation 
of leukaemic cells and this may hinder CLL cells sensitivity to ST1326 (55). 
The proliferative compartment in CLL is responsible for disease 
persistence after treatment (104; 105). Therefore, targeting this crucial 
compartment with ST1326 in combination with standard therapies, such as 
ABT-199 and Fludarabine, could be an efficient approach to try to eradicate 
both proliferative and non-proliferative compartments of CLL cells. 
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ST1326 is a well-tolerated drug and is used in clinics for diabetes treatment. 
Data of the literature also show an antiproliferative effect by two other drugs, 
Etomoxir and Perhexiline which, unlike ST1326, are irreversible inhibitors of 
CPT1 (82; 106). However, the use of these irreversible CPT1 inhibitors has been 
discouraged in the clinical practice because of excessive liver (107) and cardiac 
toxicity (108). Interestingly, in our in vitro study a ten times lower dose was 
needed for ST1326 to reach a cytotoxicity level similar to that obtained with 
Etomoxir. ST1326, possibly due to its reversibility and high selectivity for the 
CPT1A isoform, displays in vivo only low and transient liver toxicity (87). The 
doses used in our study are clinically achievable. Investigations on the 
pharmacokinetics of this aminocarnitine derivative, performed by Sigma-Tau, 
indicated that plasma levels reach drug concentrations in the high nanomolar/low 
micromolar range, particularly under fasting conditions (ST1326, Sigma-Tau 
Investigator’s Brochure, Edition no. 3, Nov 5, 2007). Notably, autoradiography 
on rats and monkeys documented drug distribution in the spleen (unpublished 
data from Sigma-Tau), one of the lymphoid tissues where CLL cells reside and 
might receive activation stimuli. Thus, the drug concentration used in our 
experiments is not far from plasma levels and could be even lower than drug 
concentration in lymphoid organs.  
 
These results demonstrate that sensitivity of CLL cells to inhibition of beta-
oxidation is much stronger in cells activated by microenvironment stimuli and 
entering proliferation than in quiescent ones, suggesting that activated leukaemic 
cells are more dependent on FAO for survival and proliferation. This notion is 
particularly important because CLL disease development and progression are 
strictly linked to the iterative re-activation cycles that occur in lymphoid tissues. 
Therefore, we feel that our results pave the way for ST1326 as a novel tool to be 
proposed in anti-CLL drug-combination therapeutic regimens, particularly with 
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